Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Chronic bronchitis (CB) is a critical component of chronic obstructive pulmonary disease (COPD). Emphysema, reversible airway disease and bronchiectasis also contribute to COPD. Elderly patients are at increased risk for COPD and its components - emphysema, CB and bronchiectasis. In addition, older patients are at increased risk for resistant organisms during episodes of acute exacerbation of CB (AECB). These organisms include the more common bacteria implicated in AECB, such as Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae, and less common nonenteric, Gram-negative organisms such as Pseudomonas aeruginosa. Risk-stratified antibiotic treatment guidelines for AECB appear to be useful, although they have not been prospectively validated for the general CB population, and especially not in the elderly CB population. Many of the AECB treatment guidelines that are stratified based on risk factors have recommended that the oral respiratory fluoroquinolone antibiotics (gemifloxacin, levofloxacin and moxifloxacin) play a second-line but pivotal role, particularly in patients who have failed initial antibiotic treatment for simple CB or as initial treatment for complicated CB.

Original languageEnglish (US)
Pages (from-to)539-548
Number of pages10
JournalExpert Review of Respiratory Medicine
Volume3
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Chronic Bronchitis
Anti-Bacterial Agents
Chronic Obstructive Pulmonary Disease
Bronchiectasis
Emphysema
Therapeutics
Guidelines
Moraxella (Branhamella) catarrhalis
Levofloxacin
Fluoroquinolones
Haemophilus influenzae
Streptococcus pneumoniae
Pseudomonas aeruginosa
Population
Bacteria

Keywords

  • Bronchiectasis
  • Bronchitis
  • COPD
  • Elderly patients

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health

Cite this

@article{5523e070cc0741c8839f0d56e1acb560,
title = "Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis",
abstract = "Chronic bronchitis (CB) is a critical component of chronic obstructive pulmonary disease (COPD). Emphysema, reversible airway disease and bronchiectasis also contribute to COPD. Elderly patients are at increased risk for COPD and its components - emphysema, CB and bronchiectasis. In addition, older patients are at increased risk for resistant organisms during episodes of acute exacerbation of CB (AECB). These organisms include the more common bacteria implicated in AECB, such as Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae, and less common nonenteric, Gram-negative organisms such as Pseudomonas aeruginosa. Risk-stratified antibiotic treatment guidelines for AECB appear to be useful, although they have not been prospectively validated for the general CB population, and especially not in the elderly CB population. Many of the AECB treatment guidelines that are stratified based on risk factors have recommended that the oral respiratory fluoroquinolone antibiotics (gemifloxacin, levofloxacin and moxifloxacin) play a second-line but pivotal role, particularly in patients who have failed initial antibiotic treatment for simple CB or as initial treatment for complicated CB.",
keywords = "Bronchiectasis, Bronchitis, COPD, Elderly patients",
author = "Albertson, {Timothy E} and Andrew Chan",
year = "2009",
doi = "10.1586/ers.09.37",
language = "English (US)",
volume = "3",
pages = "539--548",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis

AU - Albertson, Timothy E

AU - Chan, Andrew

PY - 2009

Y1 - 2009

N2 - Chronic bronchitis (CB) is a critical component of chronic obstructive pulmonary disease (COPD). Emphysema, reversible airway disease and bronchiectasis also contribute to COPD. Elderly patients are at increased risk for COPD and its components - emphysema, CB and bronchiectasis. In addition, older patients are at increased risk for resistant organisms during episodes of acute exacerbation of CB (AECB). These organisms include the more common bacteria implicated in AECB, such as Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae, and less common nonenteric, Gram-negative organisms such as Pseudomonas aeruginosa. Risk-stratified antibiotic treatment guidelines for AECB appear to be useful, although they have not been prospectively validated for the general CB population, and especially not in the elderly CB population. Many of the AECB treatment guidelines that are stratified based on risk factors have recommended that the oral respiratory fluoroquinolone antibiotics (gemifloxacin, levofloxacin and moxifloxacin) play a second-line but pivotal role, particularly in patients who have failed initial antibiotic treatment for simple CB or as initial treatment for complicated CB.

AB - Chronic bronchitis (CB) is a critical component of chronic obstructive pulmonary disease (COPD). Emphysema, reversible airway disease and bronchiectasis also contribute to COPD. Elderly patients are at increased risk for COPD and its components - emphysema, CB and bronchiectasis. In addition, older patients are at increased risk for resistant organisms during episodes of acute exacerbation of CB (AECB). These organisms include the more common bacteria implicated in AECB, such as Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae, and less common nonenteric, Gram-negative organisms such as Pseudomonas aeruginosa. Risk-stratified antibiotic treatment guidelines for AECB appear to be useful, although they have not been prospectively validated for the general CB population, and especially not in the elderly CB population. Many of the AECB treatment guidelines that are stratified based on risk factors have recommended that the oral respiratory fluoroquinolone antibiotics (gemifloxacin, levofloxacin and moxifloxacin) play a second-line but pivotal role, particularly in patients who have failed initial antibiotic treatment for simple CB or as initial treatment for complicated CB.

KW - Bronchiectasis

KW - Bronchitis

KW - COPD

KW - Elderly patients

UR - http://www.scopus.com/inward/record.url?scp=73449086726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449086726&partnerID=8YFLogxK

U2 - 10.1586/ers.09.37

DO - 10.1586/ers.09.37

M3 - Article

VL - 3

SP - 539

EP - 548

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 5

ER -